Aimmune Therapeutics CEO Jayson Dallas' 2019 pay falls 49% to $4.7M
Aimmune Therapeutics reports 2019 executive compensation
By ExecPay News
Published: April 9, 2020
Aimmune Therapeutics reported fiscal year 2019 executive compensation information on April 9, 2020.
In 2019, five executives at Aimmune Therapeutics received on average a compensation package of $2.7M, a 21% decrease compared to previous year.
Average pay of disclosed executives at Aimmune Therapeutics
Jayson D.A. Dallas, Chief Executive Officer, received $4.7M in total, which decreased by 49% compared to 2018. 63% of Dallas' compensation, or $3M, was in option awards. Dallas also received $10K in bonus, $357K in non-equity incentive plan, $575K in salary, $830K in stock awards, as well as $2K in other compensation.
Andrew Oxtoby, Chief Commercial Officer, received a compensation package of $3M. 67% of the compensation package, or $2M, was in option awards.
Eric H. Bjerkholt, Chief Financial Officer, earned $2M in 2019, a 3% decrease compared to previous year.
Douglas T. Sheehy, General Counsel, received $1.9M in 2019, which decreases by 40% compared to 2018.
Daniel C. Adelman, Chief Medical Officer, earned $1.9M in 2019, a 10% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 9, 2020.